Shadfar Bahri

Title(s)HS Assistant Clinical Professor, Molecular and Medical Pharmacology
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. EJNMMI Res. 2021 Sep 06; 11(1):84. Miller CG, Grønbæk H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. PMID: 34487283.
      View in: PubMed   Mentions:
    2. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021 Oct; 62(10):1447-1456. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. PMID: 34272322.
      View in: PubMed   Mentions:    Fields:    
    3. A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours. J Nucl Med. 2021 Jul 02. Virgolini I, Bahri S, Kjaer A, Gronbaek H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. PMID: 34215673.
      View in: PubMed   Mentions: 1     Fields:    
    4. Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Ann Nucl Med. 2021 Sep; 35(9):1022-1029. Tatekawa H, Uetani H, Hagiwara A, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 34121166.
      View in: PubMed   Mentions:    Fields:    
    5. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 Oct; 62(10):1440-1446. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. PMID: 34016732.
      View in: PubMed   Mentions: 2     Fields:    
    6. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021 Oct; 48(11):3736-3737. Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J. PMID: 33914106.
      View in: PubMed   Mentions:    Fields:    
    7. Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. J Neurooncol. 2021 May; 152(3):573-582. Tatekawa H, Uetani H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Bahri S, Pope WB, Salamon N, Ellingson BM. PMID: 33704629.
      View in: PubMed   Mentions:    Fields:    
    8. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging. 2021 Mar 10; 21(1):27. Tatekawa H, Hagiwara A, Uetani H, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 33691798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. J Neurooncol. 2020 Sep; 149(2):337-346. Tatekawa H, Hagiwara A, Uetani H, Yao J, Oughourlian TC, Bahri S, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 32929644.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1364-1369. Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L. PMID: 33305100.
      View in: PubMed   Mentions:
    11. In vivo quantification of lumbar disc degeneration: assessment of ADC value using a degenerative scoring system based on Pfirrmann framework. Eur Spine J. 2015 Nov; 24(11):2442-8. Yu HJ, Bahri S, Gardner V, Muftuler LT. PMID: 25502000.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    12. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014; 38(1):171-84. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC. PMID: 23948934.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    13. Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology. J Surg Oncol. 2014 Feb; 109(2):158-67. Chen JH, Bahri S, Mehta RS, Carpenter PM, McLaren CE, Chen WP, Fwu PT, Hsiang DJ, Lane KT, Butler JA, Su MY. PMID: 24166728.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    14. Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR. NMR Biomed. 2013 Dec; 26(12):1705-13. Chen JH, Pan WF, Kao J, Lu J, Chen LK, Kuo CC, Chang CK, Chen WP, McLaren CE, Bahri S, Mehta RS, Su MY. PMID: 23940080.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res. 2013 Feb 22; 15(1):R14. O'Sullivan TD, Leproux A, Chen JH, Bahri S, Matlock A, Roblyer D, McLaren CE, Chen WP, Cerussi AE, Su MY, Tromberg BJ. PMID: 23433249.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    16. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013; 34(2):457-68. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. PMID: 23234879.
      View in: PubMed   Mentions: 260     Fields:    Translation:HumansCells
    17. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. Clin Breast Cancer. 2012 Apr; 12(2):110-8. Kuzucan A, Chen JH, Bahri S, Mehta RS, Carpenter PM, Fwu PT, Yu HJ, Hsiang DJ, Lane KT, Butler JA, Feig SA, Su MY. PMID: 22444717.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. Comparison of breast density measured on MR images acquired using fat-suppressed versus nonfat-suppressed sequences. Med Phys. 2011 Nov; 38(11):5961-8. Chang DH, Chen JH, Lin M, Bahri S, Yu HJ, Mehta RS, Nie K, Hsiang DJ, Nalcioglu O, Su MY. PMID: 22047360.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    19. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology. 2011 Dec; 261(3):735-43. Chen JH, Bahri S, Mehta RS, Kuzucan A, Yu HJ, Carpenter PM, Feig SA, Lin M, Hsiang DJ, Lane KT, Butler JA, Nalcioglu O, Su MY. PMID: 21878615.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    20. Spatial shrinkage/expansion patterns between breast density measured in two MRI scans evaluated by non-rigid registration. Phys Med Biol. 2011 Sep 21; 56(18):5865-75. Lin M, Chen JH, Mehta RS, Bahri S, Chan S, Nalcioglu O, Su MY. PMID: 21852724.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation. Radiology. 2010 Apr; 255(1):44-52. Chen JH, Nie K, Bahri S, Hsu CC, Hsu FT, Shih HN, Lin M, Nalcioglu O, Su MY. PMID: 20308443.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    22. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009 Jun; 16(6):1619-28. Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY. PMID: 19333654.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    23. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology. 2009 Jun; 251(3):653-62. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY. PMID: 19276320.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    24. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009 Mar; 249(3):448-54. Chen JH, Feig BA, Hsiang DJ, Butler JA, Mehta RS, Bahri S, Nalcioglu O, Su MY. PMID: 19247033.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    25. Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study. Clin Drug Investig. 2009; 29(11):713-9. Schulz EG, Bahri S, Schettler V, Popov AF, Hermann M. PMID: 19813774.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys. 2008 Dec; 35(12):5253-62. Nie K, Chen JH, Chan S, Chau MK, Yu HJ, Bahri S, Tseng T, Nalcioglu O, Su MY. PMID: 19175084.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    Shadfar's Networks
    Concepts (104)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (27)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-865-g7865d7b0 on PROFILES-PWEB01.

    Copyright © The Regents of the University of California